Antagonist G-targeted liposomes for improved delivery of anticancer drugs in small cell lung carcinoma.

Animals Antineoplastic Agents / therapeutic use Drug Delivery Systems Liposomes / therapeutic use Lung Neoplasms / drug therapy Mice Oligopeptides Small Cell Lung Carcinoma / drug therapy Tissue Distribution

Journal

International journal of pharmaceutics
ISSN: 1873-3476
Titre abrégé: Int J Pharm
Pays: Netherlands
ID NLM: 7804127

Informations de publication

Date de publication:
25 Jan 2022
Historique:
received: 06 07 2021
revised: 19 11 2021
accepted: 09 12 2021
pubmed: 17 12 2021
medline: 5 1 2022
entrez: 16 12 2021
Statut: ppublish

Résumé

Ligand-mediated targeted liposomes have the potential to increase therapeutic efficacy of anticancer drugs. This work aimed to evaluate the ability of antagonist G, a peptide targeting agent capable of blocking the action of multiple neuropeptides, to selectivity improve targeting and internalization of liposomal formulations (long circulating liposomes, LCL, and stabilized antisense lipid particles containing ionizable amino lipid, SALP) to H69 and H82 small cell lung carcinoma (SCLC) cell lines. Antagonist G-targeted LCL and SALP were prepared by two different methods (either by direct covalent linkage at activated PEG grafted onto the liposomal surface or by post-insertion of DSPE-PEG-antagonist-G-conjugates into pre-formed liposomes). Association of the liposomal formulations with target SCLC cells was studied by fluorescence microscopy using fluorescence-labelled liposomes and confirmed quantitatively with [

Identifiants

DOI: 10.1016/j.ijpharm.2021.121380 PMID: 34915142
pubmed: 34915142
pii: S0378-5173(21)01186-8
doi: 10.1016/j.ijpharm.2021.121380
pii:
doi:

Substances chimiques

Antineoplastic Agents 0
Liposomes 0
Oligopeptides 0
arginyl-tryptophyl-N-methylphenylalanyl-tryptophyl-leucyl-methioninamide 115150-59-9

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

121380

Informations de copyright

Copyright © 2021 Elsevier B.V. All rights reserved.

Auteurs

Manuela Carvalheiro (M)

Instituto de Investigação do Medicamento (iMed.ULisboa), Faculdade de Farmácia, Universidade de Lisboa, Avenida Professor Gama Pinto, 1649-003 Lisboa, Portugal; Departamento de Farmácia, Farmacologia e Tecnologias em Saúde, Faculdade de Farmácia, Universidade de Lisboa, Avenida Professor Gama Pinto, 1649-003 Lisboa, Portugal.

Margarida Ferreira-Silva (M)

Instituto de Investigação do Medicamento (iMed.ULisboa), Faculdade de Farmácia, Universidade de Lisboa, Avenida Professor Gama Pinto, 1649-003 Lisboa, Portugal; Departamento de Química e Bioquímica, Faculdade de Ciências, Universidade de Lisboa, 1749-016 Lisboa, Portugal.

Denys Holovanchuk (D)

Instituto de Investigação do Medicamento (iMed.ULisboa), Faculdade de Farmácia, Universidade de Lisboa, Avenida Professor Gama Pinto, 1649-003 Lisboa, Portugal; Departamento de Química e Bioquímica, Faculdade de Ciências, Universidade de Lisboa, 1749-016 Lisboa, Portugal.

H Susana Marinho (HS)

Departamento de Química e Bioquímica, Faculdade de Ciências, Universidade de Lisboa, 1749-016 Lisboa, Portugal; Centro de Química Estrutural, Faculdade de Ciências, Universidade de Lisboa, Campo Grande, 1749-016 Lisboa, Portugal.

João Nuno Moreira (JN)

CNC - Center for Neuroscience and Cell Biology, Center for Innovative Biomedicine and Biotechnology (CIBB), University of Coimbra, Faculty of Medicine (Polo 1), Rua Larga, 3004-504 Coimbra, Portugal; UC - University of Coimbra, CIBB, Faculty of Pharmacy, Pólo das Ciências da Saúde, Azinhaga de Santa Comba, 3000-548 Coimbra, Portugal.

Helena Soares (H)

Centro de Química Estrutural, Faculdade de Ciências, Universidade de Lisboa, Campo Grande, 1749-016 Lisboa, Portugal; Escola Superior de Tecnologia da Saúde de Lisboa, Instituto Politécnico de Lisboa, 1990-096 Lisboa, Portugal.

M Luisa Corvo (ML)

Instituto de Investigação do Medicamento (iMed.ULisboa), Faculdade de Farmácia, Universidade de Lisboa, Avenida Professor Gama Pinto, 1649-003 Lisboa, Portugal; Departamento de Farmácia, Farmacologia e Tecnologias em Saúde, Faculdade de Farmácia, Universidade de Lisboa, Avenida Professor Gama Pinto, 1649-003 Lisboa, Portugal. Electronic address: lcorvo@ff.ulisboa.pt.

Maria Eugénia M Cruz (MEM)

Instituto de Investigação do Medicamento (iMed.ULisboa), Faculdade de Farmácia, Universidade de Lisboa, Avenida Professor Gama Pinto, 1649-003 Lisboa, Portugal.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Evaluating the efficacy of telesurgery with dual console SSI Mantra Surgical Robotic System: experiment on animal model and clinical trials.

Sudhir Prem Srivastava, Vishwajyoti Pascual Srivastava, Avinesh Singh et al.
1.00
Robotic Surgical Procedures Animals Humans Telemedicine Models, Animal

Odour generalisation and detection dog training.

Lyn Caldicott, Thomas W Pike, Helen E Zulch et al.
1.00
Animals Odorants Dogs Generalization, Psychological Smell

Prognostic value of the systemic immune-inflammation index in lung cancer patients receiving immune checkpoint inhibitors: A meta-analysis.

Yanhui Yang, Ji Li, Yi Wang et al.
1.00
Humans Immune Checkpoint Inhibitors Lung Neoplasms Prognosis Inflammation

Classifications MeSH

Recherchemedicale.com › Eucaryotes › Animaux › Antagonist G-targeted liposomes for improved...
Recherchemedicale.com › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antinéoplasiques › Antagonist G-targeted liposomes for improved...
Recherchemedicale.com › Thérapeutique › Traitement médicamenteux › Systèmes de délivrance de médicaments › Antagonist G-targeted liposomes for improved...
Recherchemedicale.com › Technologie, industrie et agriculture › Produits manufacturés › Matériaux biomimétiques › Membrane artificielle › Liposomes › Antagonist G-targeted liposomes for improved...
Recherchemedicale.com › Maladies de l'appareil respiratoire › Tumeurs de l'appareil respiratoire › Tumeurs du poumon › Antagonist G-targeted liposomes for improved...
Recherchemedicale.com › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Antagonist G-targeted liposomes for improved...
Recherchemedicale.com › Acides aminés, peptides et protéines › Peptides › Oligopeptides › Antagonist G-targeted liposomes for improved...
Recherchemedicale.com › Maladies de l'appareil respiratoire › Tumeurs de l'appareil respiratoire › Tumeurs du poumon › Tumeurs des bronches › Carcinome bronchogénique › Carcinome pulmonaire à petites cellules › Antagonist G-targeted liposomes for improved...
Recherchemedicale.com › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Pharmacocinétique › Distribution tissulaire › Antagonist G-targeted liposomes for improved...